NCT01866423View on ClinicalTrials.gov

Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 25, 2013

Primary Completion Date

July 23, 2015

Study Completion Date

July 26, 2016

Conditions
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer
Interventions
DRUG

orteronel

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

90033

USC Norris Comprehensive Cancer Center, Los Angeles

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

University of Southern California

OTHER